Nuformix (NFX) appointed Dr Karl Keegan to the board as Non-Executive Director on Tuesday as it replaces Mr. Dave Tapolczay who left earlier this month.
The pharmaceutical development company focused on cocrystal technology hired Mr. Karl Keegan to bring a new specialist life sciences experience to the board.
Dr. Keegan is currently Chief Executive Officer and Executive Board member at HOX Therapeutics Ltd, a private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes, and before that spent 12 years as a highly regarded sell-side life sciences research analyst, researching and helping finance companies across the UK, Europe, USA and Canada.
Dr Dan Gooding, Chief Executive Officer of Nuformix Plc, commented: "I am delighted to welcome Karl to the Nuformix Board.”
He said: “With his extensive experience in strategy, finance, corporate development and capital markets within life sciences, Karl brings a wealth of experience that is highly relevant to Nuformix at this moment as we enter new stages in the development of the Company and our assets."
Share ticked up 4.44% to 7.05p during Tuesday morning trading
Recently, Dr. Keegan has focused on corporate development, and has a successful track record of devising and implementing M&A and finance projects, delivering value across all aspects of business strategy, Nuformix said.
Dr. Keegan worked on the sale of Minster pharmaceuticals plc to Proximagen plc, multiple financings to support a new strategy for Pharming Group NV, and leadership of M&A deals at Vectura Group plc.
Dr. Keegan graduated from University College Dublin, Ireland in 1988 with a B.Sc. in Pharmacology and gained M.Phil. and Ph.D. degrees (Pharmacology) from the University of Cambridge (UK) where he was funded by a Parke-Davis Research Scholarship.
In 2005 he completed a M.Sc. in Finance at the London Business School, focussing on entrepreneurial finance and valuation of early stage businesses.
Follow News & Updates from Nuformix here: